Sentences with phrase «autologous cells»
"Autologous cells" refers to cells that are taken from a person's own body and then used for medical purposes, such as in transplants or therapies. These cells are considered unique to each individual and are less likely to be rejected by the body compared to cells from a different person. Full definition
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.
regmednet.com
The generation of mesenchymal stem cells (MSCs) from patient - specific induced pluripotent stem cells (iPSCs) may represent a convenient source of autologous cells for therapeutic purposes.
The author mentions that for autologous cell therapy it may be possible to use these cells without full FDA approval («injected with his or her own cells — full FDA approval may not be required; simply registering the therapy and getting patient consent could be enough.»).
Similarly, some conditions contraindicate autologous cell harvest.
Autologous cells used to infect mice that were not transduced were obtained and stimulated simultaneously as the initially engrafted cells.
Possible solutions can be provided by use of MSCs, which are known for their immunomodulatory properties, iPSCs, which are derived from the patient's own tissue, and of course autologous cell sources.
«If we win, the entire regulatory structure for autologous cell processing, with or without culture, will be rewritten such that any physician using good practices and treating patients responsibly can use stem cells as part of his or her medical practice,» he says.
So, autologous cells derived from the patient can be used to treat devastating neurogenic diseases that are currently hampered by the lack of easily accessible cell sources.»
In conclusion, here we report a novel and promising therapeutical approach that is safe, cost effective, and relying only on autologous cells.
For instance, during emergency care, allogeneic therapy is usually the only relevant option due to the time constraints of autologous cell expansion.
Although autologous cell transplantation circumvents the need for immunosuppressive treatment, it is not always available or most effective.
iPSC - based cell therapy enables to advance personalized medicine by utilizing autologous cells.
The use of autologous cell products in «non-homologous» applications will require full FDA approval.
Manufacturing Models Permitting Roll - Out / Scale - Out of Clinically Led Autologous Cell Therapies: Regulatory and Scientific Challenges for Comparability.
Autologous cells harvested from the patient, expanded ex vivo and then introduced back into the patient's body.
Meeting scalability challenges for autologous cell - based manufacturing with automated closed - system solutions
A pericardial flap, made of autologous cells from the patients, covers the patch, providing trophic factors to the ES progenitors.
«This work has the potential to provide a novel source of abundant, easily accessible and autologous cells for treatment of devastating neurodegenerative diseases.
Further, if you can use the child's own cells, or autologous cells, you wouldn't have to give chemotherapy to prevent rejection and the cells would be accepted because they are the same genetic material as the child.
In part 2, we continue to analyze manufacturing costs of an autologous cell therapy.
Additionally, genetic modification or pre-conditioning of autologous cells to boost the levels of VEGF [4], ANG [5], and TGF -[6], all previously linked to alleviation of ALS symptoms, could potentially lead to an augmented response, although this must first be assessed in animal models, such as the SOD1 mice.
RepliCel's autologous cell therapy, RCS - 01, to be investigated as a potential treatment for aged and UV - damaged skin.
Cost Analysis of Cell Therapy Manufacture: Autologous Cell Therapies, Part 1 To ensure that autologous cell therapies can meet patient needs, manufacturing processes must be consistent across multiple operators and process steps to ensure compliance with established product quality standards.